Pfizer…and innovation emergencies

The news that Pfizer is to close its R&D facility in Sandwich in Kent has shaken us from our sleepy winter hollows. I’ve been watching the reactions and comments come over the wires as I am sure you have.  This is clearly a company going through considerable transition as it tries to change with the […]

An evening of industry – how the pharma business model is changing

So it’s 10pm and I’m busy here putting the final touches to the AMRC/INVOLVE report of the workshop we held in November which drew together patient views on health research regulation.  This was at the invitation of the Academy of Medical Sciences as part of their review of regulation and governance but – and all […]

When good medicine is the casualty of hype and ignorance

I have just returned from the Financial Times’ offices, where I was the guest for their regular science podcast hosted by Clive Cookson and Andrew Jack (it will appear here later today).  The theme of the discussion was ‘Selling Sickness.’  Andrew was reporting on a recent conference of the same name that took place last month in Holland.  […]

Capability Dave announces cluster therapy for research

Monday saw the Science Mnister, David Willetts, and Health Minister, Earl Howe, announce what are being called therapeutic capability clusters (research consortia)  at the ABPI/BIA conference in London.  PharmaLetter has an article on it and what I think is the formal news release can be found on Pharma Live. Don’t be fooled by the PR […]

Science at the Labour Party Conference – Ed captures hearts but not science

In my potter around the conference exhibition this afternoon, I stumbled upon a stand for the ‘People’s Museum’ here in Manchester which charts the struggles of the working class and houses the Labour Party’s official archives. I wish I had time to pop along if only to check whether my knowledge of political history is […]